Reconstitution of peripheral allospecific CD19+ B-cell subsets after b-lymphocyte depletion therapy in renal transplant patients

Transplantation

Volumn 87, Issue 9, 2009, Pages 1394-1401

  Kopchaliiska, Dessislava ^a   Zachary, Andrea A ^a   Montgomery, Robert A ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allospecific B lymphocytes; B cell depletion; Memory B cells; Repopulation of B cells; Transitional B cells

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; CD20 ANTIBODY; CD27 ANTIBODY; CD38 ANTIBODY; FLUOROCHROME; HLA ANTIBODY; HLA ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; BASE MISPAIRING; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLENECTOMY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD19; B-LYMPHOCYTE SUBSETS; FEMALE; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; SPLENECTOMY; TRANSPLANTATION, HOMOLOGOUS;

EID: 67649619522     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a27683     Document Type: Article

References (37)

1. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
2. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181.
3. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033.
4. Zachary AA, Montgomery RA, Leffell MS. Desensitization protocols improving access and outcome in transplantation. Clin Appl Immunol Rev 2005; 5: 373.
5. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch:Asingle center's perspective. Pediatr Transplant2004; 8: 535.
6. Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases [review]. Annu Rev Med2004; 55: 477.
7. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315.
8. Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4: 561.
9. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19: 621.
10. Faguer S, Kamar N, Guilbeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation2007; 83: 1277.
11. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
12. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
13. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88: 637.
14. Golay J, Zaffaroni L, Vaccari T, et al. Biological response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 92: 3900.
15. Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subsets recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55.
16. Genberg H, Hansson A, Wernerson A, et al. Pharmacodynamics of rituximab in kidney allotransplantation.AmJ Transplant 2006; 6: 2418.
17. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant2007; 7: 402.
18. Steinmetz OM, Lange-Husken F, Turner JE, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007; 84: 842.
19. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377.
20. Leandro M, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613.
21. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139.
22. Pers JO, Daridon C, Bendaoud B, et al. B-cell depletion and repopulation in autoimmune diseases. Clinic Rev Allerg Immunol 2008; 34: 50.
23. Zachary AA, Kopchaliiska D, Montgomery R, et al. HLA-specific B cells. I. A method for their detection, quantification, and isolation using HLA tetramers. Transplantation 2007; 83: 982.
24. Zachary AA, Kopchaliiska D, Montgomery R, et al. HLA-specific B cells. II. Application to transplantation. Transplantation 2007; 83: 989.
25. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation, Part 1: Safety, pharmacodynamics and pharmacokinetics. Transplantation2004; 77: 542.
26. Yoshizawa A, Sakamoto S, Ogawa K, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: The use of rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 2005; 37: 1718.
27. Garrett HE Jr, Duvall-Seaman D, Helsley B, et al. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24: 1337.
28. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354: 1961.
29. Jordan SC, Pescovitz MD. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
30. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044.
31. Avanzini MA, Locatelli F, Santos CD, et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: Functional immaturity and slow recovery of memory CD27- B cells. Exp Hematol 2005; 33: 480.
32. Marie-Cardine A, Divay F, Dutot I, et al. Transitional B cells in humans: Characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 2008; 127: 14.
33. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301: 1374.
34. Egawa H, Ohmori K, Haga H, et al. B-cell surface marker analysis for improvement of rituximab prophilaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 2007; 13: 579.
35. Cambridge G, Stohl W, Leandro M, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723.
36. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation2008; 85: 1648.
37. Cambridge G, Isenberg D, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011.